Published in final edited form as:

Vet Comp Oncol. 2012 September ; 10(3): 194–205. doi:10.1111/j.1476-5829.2011.00275.x.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumors

Cheryl London¹, Tamra Mathie¹, Nicole Stingle¹, Craig Clifford², Siobhan Haney², Mary K. Klein³, Linda Beaver³, Kate Vickery³, David M. Vail⁴, Betsey Hershey⁵, Susan Ettinger⁶, Andrew Vaughan⁷, Francisco Alvarez⁸, Lorin Hillman⁹, Mike Kiselow¹⁰, Doug Thamm¹¹, Mary Lynn Higginbotham¹², Meredith Gauthier¹³, Erika Krick¹⁴, Brenda Phillips¹⁵, Tracy LaDue¹⁶, Pam Jones¹⁷, Jeffery Bryan¹⁸, Virginia Gill¹⁹, Andrew Novasad²⁰, Lisa Fulton²¹, Janet Carreras²², Conor McNeill²³, Carolyn Henry²⁴, and Sarah Gillings²⁵

¹The Ohio State University, Columbus, OH

²Red Bank Veterinary Hospital, Tinton Falls, NJ

³Southern Arizona Veterinary Specialty and Emergency Center, Tuscon, AZ

⁴University of Wisconsin, Madison, Madison, WI

⁵Integrative Veterinary Center, Phoenix, AZ

⁶Animal Specialty Center, Yonkers, NY

⁷Las Vegas Veterinary Referral Center, Las Vegas, NV

⁸Coral Springs Animal Hospital, Coral Springs, FL

⁹MedVet Memphis, Memphis, TN

¹⁰Veterinary Medical Specialists, San Mateo, CA

¹¹Colorado State University, Fort Collins, CO

¹²Kansas State University, Manhattan, KS

¹³Mississauga Oakville Veterinary Emergency Hospital

¹⁴University of Pennsylvania, Philadelphia PA

¹⁵Veterinary Specialty Hospital of San Diego, San Diego, CA

¹⁶Southeast Veterinary Oncology, Orange Park, FL

¹⁷Capital Area Veterinary Specialists, Austin, TX

¹⁸Washington State University, Pullman, WA

¹⁹Katonah-Bedford Veterinary Center, BRIGHTHEART Veterinary Centers, Bedford Hill, NY

²⁰Sugar Land Veterinary Specialists, Sugar Land, TX

²¹MedVet Medical Center, Columbus, OH

²²Gulf Coast Veterinary Specialists, Houston, TX

²³The Hope Center for Advanced Veterinary Medicine, Vienna, VA

Corresponding Author: Cheryl London, 1025 Coffey Road, VMAB 454, The Ohio State University, Columbus, OH, 43214. Phone: 614-292-9554, Fax: 614-292-7599, Cheryl.London@cvm.osu.edu.

Presented in abstract form at the 30th Annual Conference of the Veterinary Cancer Society, San Diego, CA, October 2010.

²⁴University of Missouri, Columbia, MO

²⁵Animal Cancer Specialists, Seattle, WA

Abstract

The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®) in select solid tumors in dogs. Cases in which toceranib was used to treat dogs with anal sac anal gland adenocarcinoma, metastatic osteosarcoma, thyroid carcinoma, head and neck carcinoma, and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 anal sac tumors (8PR, 20SD), 11/23 osteosarcomas (1PR, 10SD), 12/15 thyroid carcinomas (4PR, 8SD), 7/8 head and neck carcinomas (1CR, 5PR, 1SD) and 5/7 (1CR, 4SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg/kg, 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis, and 47/63 (74.6%) were treated 4 months or longer. While these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumors, future prospective studies are necessary to define its true activity.

Keywords

toceranib; dog; tumor; carcinoma; sarcoma

Introduction

Toceranib phosphate (Palladia®) is a small molecule inhibitor that blocks a variety of tyrosine kinases expressed on the cell surface; these are known as receptor tyrosine kinases (RTK) ¹⁻³. It works as a competitive inhibitor of ATP, thereby preventing receptor phosphorylation and subsequent downstream signal transduction. Targets of toceranib include several members of the split kinase family such as VEGFR, PDGFR, Kit, CSF-1, and Flt-3 ¹⁻³. Based on its structural and functional similarity to sunitinib (Sutent) toceranib likely also inhibits an additional RTK called Ret ^{4,5}. Toceranib was originally developed as an anti-angiogenic agent as inhibition of VEGFR and PDGFR family members limit angiogenesis in a variety of murine tumor models ^{6,7}. However, inhibition of other members of the split kinase family such as Kit and possibly Ret can result in direct anti-tumor activity as well ⁸⁻¹⁰.

The first evaluation of toceranib in dogs with cancer was a phase I clinical trial exploring its safety and activity¹. In 57 dogs with a variety of tumors (carcinomas, sarcomas, mast cell tumors [MCTs], melanomas, and lymphomas) objective responses occurred in 16 dogs (28%) with stable disease in an additional 15 dogs for an overall biological activity of 54%. Responding tumors included sarcomas, carcinomas, melanomas, myeloma, and MCTs. The highest response rate was in MCTs, with 13/22 dogs with Kit mutations exhibiting responses (n=11) or stable disease (n=2). A placebo controlled randomized field study of toceranib was then performed in dogs with nonresectable Grade II and III MCTs². During the blinded phase, the response rate in toceranib treated (n=86) dogs was 37.2% (7 CR, 25 PR) versus 7.9% (5 PR) in placebotreated (n=63) dogs. Of 58 dogs that received toceranib following placebo-escape, 41.4% (8 CR, 16 PR) experienced an objective response. The overall response rate for all 145 dogs receiving toceranib was 42.8% (21 CR, 41 PR). These two clinical trials demonstrated that toceranib has biologic activity in canine MCTs and possibly has activity in a variety of other tumor types either through inhibition of angiogenesis, direct anti-tumor effects, or a combination of both. Toceranib was approved by the FDA for the treatment of canine MCTs in June 2009. Since that time, dogs with a variety of non-MCT histologies have been treated with toceranib, either alone or as part of a metronomic protocol

in which low doses of chemotherapy (usually cyclophosphamide or chlorambucil) often combined with a non-steroidal anti-inflammatory drug (NSAID) is used to inhibit neo-angiogenesis in tumors. Anecdotal evidence of potential biologic activity of toceranib has been reported in several solid tumors including anal sac adenocarcinomas and thyroid carcinomas.

The toceranib label indicates dosing should be initiated at 3.25 mg/kg (the maximum tolerated dose, MTD) every other day (EOD) and dose reduced as needed based on clinical side effects². While 3.25 mg/kg has been established as the MTD, clinical evidence exists that good biologic activity occurs when doses are initiated below the 3.25 mg/kg rate and flexible dosing schedules may also be effective. For example, in the Phase I study, of 16 dogs treated with toceranib at 2.5 mg/kg EOD, 6/16 (37.5%) exhibited response to therapy (4 complete and 2 partial) while an additional 5 dogs had stable disease for greater than 10 weeks¹. This compares favorably with 20 dogs treated with 3.25 mg/kg EOD in which 8 (40%) had objective responses (2 complete and 6 partial) and an additional 4 dogs had stable disease for 10 weeks. Based on these data in a small number of patients, it is possible that lower doses of toceranib will still be associated with clinical activity. This is important as at 2.5-2.75 mg/kg EOD may be better tolerated than the higher dose, resulting in fewer adverse events (AEs), better owner compliance, and importantly, fewer drug holidays (shorter periods of drug discontinuation).

The purpose of the following study was to survey the Oncology Listserve to gain additional information regarding tumor histologies that may be responsive to toceranib, to identify dosing regimens currently employed by those using toceranib, and to provide preliminary data regarding the impact of dose rate and regimen on biologic activity of toceranib. Such information represents a critical prerequisite for the design and implementation of future prospective clinical investigations to determine the true activity of toceranib for treating additional histologies.

Materials and Methods

Case Selection

The American College of Veterinary Internal Medicine (ACVIM) Oncology Listserve, an e-mail based forum for case discussion among Oncology Diplomates, was used to solicit for information regarding cases in which toceranib phosphate was used to treat dogs with several different solid tumors including anal gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinomas (squamous cell carcinoma, SCC; ceruminous gland carcinoma) and nasal carcinoma. Cases were eligible for analysis if all of the following information was available: signalment (breed, age, gender), cytologic or histologic confirmation of tumor, previous treatment, documentation of gross disease prior to initiation of toceranib, toceranib dose and schedule, at least one documented response assessment (except for nasal tumors), duration of toceranib therapy, duration of response to therapy, concomitant medications (including NSAIDs and other metronomic drugs) and reported AEs.

Response to therapy

Response to therapy was defined as complete response (CR, resolution of all target and non-target lesions, no new lesions), partial response (PR, at least 30% decrease in the longest diameter of target lesions, no progression of non-target lesions, and no new lesions), stable disease (SD, decrease in target lesions of less than 30% or increase of target lesions less than 20%, no progression of non-target lesions, and no new lesions for at least 10 weeks) or progressive disease (PD, greater than 20% increase in target lesions, progression of non-

target lesions, new lesions). Dogs were defined as experiencing clinical benefit (CB) if they had CR, PR, or SD.

Data analysis

Given the retrospective nature of the study and the informal manner in which data was collected, it was not subjected to formal statistical analysis. However, descriptive statistics were performed on the following factors: age, gender, weight, toceranib dose, toceranib schedule, toceranib regimen, response to therapy, duration of response, duration of therapy, and the use of NSAIDs and cyclophosphamide.

Results

Dogs

There were 85 cases with sufficient information for inclusion into the analysis and patient demographics are provided in Table 1. The median age of all dogs was 10 years and most were either spayed females (n=40) or neutered males (n=41). The most common breeds represented were mixed breed (n=19), Labrador retriever (n=16), Golden retriever (n=9), Greyhound (n=4) and 3 each of German shepherd, Shetland sheepdog, and beagle. There were 32 cases of AGASACA, 23 cases of metastatic OSA, 15 cases of thyroid carcinoma, 8 cases of head and neck carcinomas, and 7 cases of nasal carcinoma included in this retrospective analysis.

Response to therapy

Anal sac anal gland adenocarcinoma—Of the 32 dogs with AGASACA treated with toceranib, there were 9 Labrador retrievers and 2 Labrador mixed breed dogs suggesting that his breed may be overrepresented. The median age of all dogs was 11 years (range 7-18), 13 were spayed females and 19 were neutered males. Prior therapy (surgery, chemotherapy, radiation therapy, or a combination of these) had been given to 25/32 dogs and 7 were hypercalcemic secondary to disease. Metastasis was present in most dogs (n=28) including sublumbar lymph nodes (n=25), lungs (n=9), liver (n=2) and other sites (n=11). The median toceranib dose used was 2.81 mg/kg (mean, 2.81 mg/kg, range 2.2-3.25 mg/kg). Most of the dogs (22/32, 68.8%) were treated on a Monday, Wednesday, Friday (MWF) schedule with the remainder receiving drug every other day (EOD, n=8) or twice per week (n=2). Of the 32 dogs treated, 8 (25%) experienced partial response (PR) and 20 (62.5%) experienced stable disease (SD) for a clinical benefit (CB) rate of 87.5%. Examples of two dogs with metastatic AGASACA that experienced PR to toceranib therapy are shown in Figure 1. The median duration for PR was 22 weeks (mean, 23.1 weeks, range 10-40 weeks) and the median duration for SD was 30.5 weeks (mean 30.9, range 10-47). The median duration of treatment for all 32 dogs treated with toceranib was 25 weeks (range, 0-47+ weeks).

Metastatic osteosarcoma—To be included in this retrospective analysis, dogs must have had radiographic evidence of pulmonary metastatic disease as it was not considered possible to accurately assess primary bone lesions for response to therapy. Of the 23 dogs with OSA treated with toceranib, there were 4 mixed breeds, 4 Golden retrievers, 3 Labrador retrievers, 3 Greyhounds, with the remainder a variety of other primarily large breed dogs. The median age of all dogs was 9 years (range 3-12 years), 13 were spayed females, and 10 were neutered males. Nearly all dogs (21/23) had undergone surgery to remove the primary tumor and received chemotherapy prior to the development of metastasis; one dog had received no treatment and one dog had received palliative radiation therapy only. One dog had a metastatic lesion in the triceps muscle in addition to pulmonary metastasis. The median toceranib dose used was 2.7 mg/kg (range 2.3-3.25 mg/kg). Approximately half of the dogs (13/23, 56.5%) were treated on a MWF schedule with the remainder receiving drug

EOD. Of the 23 dogs treated, 1 (4.3%) experienced PR and 10 (43.5%) experienced SD for a CB rate of 47.8%. Figure 2 shows thoracic radiographs from a dog that experienced stable pulmonary metastasis following toceranib therapy. The median duration of treatment for the 11 dogs that experienced CB was 24 weeks (range 10-42+ weeks).

Thyroid carcinoma—Of the 15 dogs with thyroid carcinoma treated with toceranib, there were 4 mixed breeds, 2 Labrador retrievers, 2 beagles, with the remainder a variety of other breeds. The median age of all dogs was 10 years (range 7.5-13 years), 9 were spayed females, 2 were intact males, and 4 were neutered males. Prior therapy had been given to 10/15 dogs including surgery (n=4), chemotherapy (n=7) and radiation therapy (n=3). None of the dogs had clinical evidence of hyperthyroidism and of T4 levels of the 6 dogs for which this was performed were normal. The primary tumor was present in 13 dogs, 9 dogs had metastatic disease to the lungs and 1 dog had metastatic disease to the liver and spleen. The median toceranib dose used was 2.75 mg/kg (range 2.47-3.25 mg/kg). More than half of the dogs (9/15, 60%) were treated on a MWF schedule with the remainder receiving drug EOD (n=5) or every third day (n=1). Of the 15 dogs treated, 4 (26.7%) experienced PR and 8 (53.3%) experienced SD for a CB rate of 80%. Figure 3 shows two dogs with pulmonary metastasis that experienced PR or SD following toceranib therapy. The median duration of treatment for the 12 dogs that experienced CB was 24.5 weeks (range 11-50+ weeks).

Head and neck carcinoma—There were 8 dogs with head and neck carcinomas including 3 squamous cell carcinomas (SCC) of the nasal planum, 4 SCC of the oral cavity (mandible, maxilla, lingual) and one dog with a ceruminous gland adenocarcinoma. There were 3 mixed breeds, 2 Labrador retrievers, and 2 Golden retrievers, and one Boxer. The median age was 11.5 years (range 10-13 years), and there were 3 spayed females, 2 intact males, and 3 neutered males. The majority (n=5) had received no prior treatment, while 2 had undergone surgery and 1 had completed radiation therapy. Metastasis to the mandibular nodes was present in 2 dogs and to the lungs in one dog. The median toceranib dose used was 2.87 mg/kg (range 2.5-3.2 mg/kg). Half of the dogs were treated on a MWF schedule and half received drug EOD (n=5). Of the 8 dogs treated, 1 (12.5%) experienced CR, 5 experience PR (62.5%), 1 experienced SD although this was not of sufficient duration to meet criteria for inclusion, and 1 experienced PD for a CB of 75%. Figure 4 shows a dog with an oral SCC that responded to toceranib therapy. The median duration of treatment for the 6 dogs that experienced CB was 19.5 weeks (range 4-48+ weeks).

Nasal carcinoma—There were 7 dogs with nasal carcinoma eligible for inclusion in the analysis. The median age was 10 years (range 8-13 years), and there were 3 spayed females and 4 neutered males. The majority (n=4) had received prior radiation therapy, and metastasis to the lymph nodes was present in 2 dogs and to the lungs in 1 dog. The median toceranib dose used was 2.67 mg/kg (range 2.4-3.2 mg/kg). Six of the dogs were treated on a MWF schedule and only 1 received drug EOD. Responses in the nasal tumors are difficult to assess without serial CT and only 2/7 dogs had imaging performed following initiation of toceranib. Therefore, for those dogs with no repeat CT, evidence of biologic activity was considered positive if clinical signs (epistaxis, nasal obstruction) improved and these dogs were considered to have experienced CB. Of the two dogs that were re-imaged, 1 had a CR and 1 had SD and an additional 3 dogs experienced CB for an overall CB rate of 71.4%. Figure 5 shows serial CT scans from a dog with nasal carcinoma that experienced a CR to toceranib therapy. The median duration of treatment for the 5 dogs that experienced CB was 18 weeks (range 12-20+ weeks).

Toceranib dose and regimen

Data regarding toceranib dose and regimen for all 85 dogs are summarized in Table 1. CB secondary to toceranib therapy was noted in 63 (74%) cases (2CR, 18PR, 43SD) and the median dose for all 85 dogs was 2.8mg/kg (range 2.2-3.25). Within the 63 dogs that experienced CB, 37 (59%) were dosed on a MWF basis, 46 (73%) received less than 3 mg/kg, and 47 (75%) were on therapy for 4 months or longer. The median dose was 2.8 mg/kg for dogs that experienced SD and the median dose was 2.8 mg/kg for dogs with PR/CR. These data did not differ from the 20 dogs that experienced PD: The median dose of toceranib was 2.8 mg/kg, 13 (59%) were dosed on a MWF basis and 14 (64%) received less than 3 mg/kg.

Influence of metronomic treatments

Metronomic therapy is now being used in canine cancer therapy as part of a variety of therapeutic regimens. As previously mentioned, this generally involves the use of an NSAID and a chemotherapeutic given at a low dose continuously. The chemotherapeutic agent typically used is cyclophosphamide at 10-12 mg/m². In this study, approximately half (n=43, 51%) of the dogs received either an NSAID alone (n=17) cyclophosphamide alone (n=14) or both n=12. Within the dogs that experienced CB, 33 (52%) received an NSAID (n=11), cyclophosphamide (n=12) or both (n=10). Although formal statistical analysis was not performed, this did not differ substantially from dogs that experienced PD; 10 (45%) received an NSAID (n=6), cyclophosphamide (n=2) or both (n=2).

Clinical toxicities

Clinical toxicities associated with toceranib administration are primarily gastrointestinal in nature but also include muscle pain/weakness and neutropenia. While side effects occurred in 66 (77.6%) of dogs in this retrospective analysis, it was sometimes difficult to directly attribute these toxicities to toceranib administration given the advanced disease state of many dogs. Nevertheless, in order of their frequency the reported toxicities were as follows: diarrhea (n=44, 51.8%), anorexia (n=30, 35.3%), vomiting (n=16, 18.8%), musculoskeletal pain and/or weakness (n=16, 18.8%), weight loss (n=15, 17.6%), positive hemocult (n=13, 15.3%), lethargy (n=11, 12.9%), neutropenia (n=9, 10.6%), and skin disorder (depigmentation, pyoderma, n=6, 7.1%).

Discussion

Toceranib phosphate (Palladia®) is an orally bioavailable multi-targeted receptor tyrosine kinase (RTK) inhibitor active against several members of the split-kinase family including VEGFR, PDGFR and Kit^{1, 2}. Toceranib is closely related to the small molecule inhibitor sunitinib (Sutent) that is active against VEGFRs 1, 2, and 3, PGFDR α and β , Flt-3, Kit, CSF-1, and Ret^{4, 9}. Sunitinib and toceranib were developed as anti-angiogenic agents based on their inhibition of VEGFR and PDGFR, two receptor families known to play an important role in tumor driven angiogenesis. Given that toceranib was developed as an anti-angiogenic agent, biologic activity in a broad range of tumors without obvious driver mutations might be expected. In support of this, sunitinib has demonstrated single agent activity in gastrointestinal stromal tumors, renal cell carcinoma, thyroid carcinoma, insulinoma, angiosarcoma and hepatocellular carcinoma^{5, 8, 9}. Furthermore, in the phase I study of toceranib, partial responses and stable disease were noted in a variety of cancers including metastatic carcinoma, transitional cell carcinoma, multiple myeloma, melanoma, and metastatic sarcoma². These data suggest that toceranib may have anti-tumor activity beyond primarily Kit driven MCTs. The purpose of this retrospective analysis was to provide preliminary information regarding the potential biologic activity of toceranib in

several solid canine tumors and as a secondary endpoint to survey the toceranib dose and dosing regimen used in the treatment of dogs with these tumors.

Biologic activity in the 85 dogs eligible for inclusion in this study was reported as 74%, with the majority of dogs experiencing SD (n=43, 68.3%). Based on the mechanism of action of toceranib and the clinical activity of other anti-angiogenic therapies in the human arena, it is not surprising that most dogs experienced SD or slowed disease progression rather than disease regression. Interestingly, the median duration of therapy for dogs with SD was 24.5 weeks (range 10-50+ weeks) indicating that many dogs benefited from drug for approximately 6 months or longer.

The overall objective response rate to toceranib was 31.7% (n=20) and most of these occurred in dogs with AGASACA (8PR), thyroid carcinoma (4PR) and head and neck carcinomas (1CR, 5PR). These objective responses suggest that specific RTKs targeted by toceranib may be dysregulated in these tumor types. In human thyroid carcinomas, objective responses to several small molecule inhibitors have been documented¹¹⁻¹³. It is now evident that human papillary and follicular thyroid carcinomas possess a number of somatic mutations including those involving Ras, the cytoplasmic kinase BRAF, and the receptor tyrosine kinase Ret¹². In clinical trials of the multi-targeted (VEGFR, PDGFR, BRAF) small molecule inhibitor sorafenib, objective response rates ranged from 10-25% and approximately 50% of patients experienced stable disease for 6 months or longer¹⁴⁻¹⁶. Recently, sunitinib has demonstrated single agent activity against human differentiated thyroid carcinomas; phase II clinical trials of this drug are currently ongoing^{11, 17}. In contrast to the human disease, the molecular biology of canine thyroid carcinomas has not been investigated and as such, the basis for response to toceranib is not known.

In human oncology, anti-angiogenic agents such as bevacizumab have shown promise for the treatment of head and neck carcinomas, particularly when used in combination with conventional chemotherapy and radiation therapy¹⁸. These tumors are known to produce VEGF and express VEGFRs indicating that an autocrine loop of stimulation may exist^{19, 20}. However, both sorafenib and sunitinib have demonstrated little to no single agent activity suggesting that the tumor cells are not dependent on VEGF/VEGFR signaling for survival^{18, 21, 22}. The molecular biology of canine head and neck carcinomas has not been evaluated so the underlying mechanisms responsible for the observed objective responses to toceranib are not known. It is interesting, however, that the biologic activity of toceranib in canine head and neck carcinoma appears to be much higher than that of sunitinib in the human disease. Tobacco exposure (smoking, chewing) is an established risk factor for the development of human head and neck carcinomas and not an obvious cause of the canine disease so it is possible that the molecular drivers responsible for the canine tumors are unique. As AGASACA is not a tumor that occurs in humans, no parallels can be drawn. While the molecular mechanisms that underlie AGASACA in dogs are not known, research in the laboratory of the corresponding author (London) indicates that both RET and VEGFR2 are expressed in these tumors.

One of the goals of this study was to survey the toceranib dose and dosing regimen used to treat dogs with solid tumors. Interestingly, the median dose used in dogs that experienced PD was 2.7 mg/kg compared to 2.8 mg/kg for dogs that experienced CB suggesting that doses below the MTD of 3.25 mg/kg are not necessarily associated with a lower biologic activity. These findings are also consistent with data from the phase I study in which no difference in biologic activity was noted between 2.5 mg/kg and 3.25 mg/kg dosing cohorts¹. A clinical trial is currently underway to evaluate the pharmacokinetics of lower doses of toceranib (2.5 mg/kg and 2.75 mg/kg) in dogs with cancer and compare this with the known drug exposure obtained with the label dose of 3.25 mg/kg.

In addition to a lower dose, over half of the dogs were treated on a MWF basis as opposed to the label recommendation of EOD. There was no difference in the proportion of dogs treated MWF that experienced PD (59%) versus CB (59%). It is interesting to note that while the median dose of toceranib used in dogs that experienced CR/PR was 2.8 mg/kg, only 35% received drug MWF suggesting that more frequent dosing may be associated with an increase in objective response to therapy. Future studies would be necessary to evaluate the true impact of alternative dosing regimens on toceranib's activity.

The clinical toxicities observed in this study were similar to those previously reported including primarily diarrhea, anorexia, vomiting and musculoskeletal pain/weakness. Interestingly, while the incidence of diarrhea was comparable to that found in the field study of toceranib in MCTs, the rates of anorexia, vomiting, lethargy, and neutropenia were substantially lower². There are several possible explanations for this observation, including a lack of standardized reporting for adverse events resulting in underreporting, the use of altered dose/dosing regiment that may be associated with better tolerability, and the absence of malignant mast cell disease that could have been a contributing factor to at least some of the gastrointestinal toxicity observed in the field study.

Recently clinical trials in human oncology have sought to combine inhibitors of the VEGF/VEGFR axis with low dose chemotherapy to more effectively target tumor angiogenesis. The majority of these studies have combined bevacizumab with low dose cyclophosphamide, and other chemotherapeutics including capecitabine, 5-fluoruracil, and methotrexate²³. While not typical, a COX-2 inhibitor is sometimes included in the protocol. The success of such regimens in human cancer patients is highly variable. In advanced drug-resistant breast cancer, the combination of bevacizumab with low dose cyclophosphamide and capecitabine or cyclophosphamide and methotrexate resulted in objective response rates of 32-48% with SD in an additional 32-41% of patients^{24, 25}. In contrast, the use of combined celecoxib and cyclophosphamide in metastatic renal cell carcinoma and refractory pediatric tumors of various types resulted in a CB rate of only 12.5%, and 6% respectively^{23, 26, 27}. In the current study, while a significant number of dogs received an NSAID, low dose cyclophosphamide, or both, there was wide variation in the type of NSAID used, dosing protocol for cyclophosphamide, and duration of use, precluding any firm conclusions. However, there was no obvious evidence that the administration of an NSAID, low dose continuous cyclophosphamide, or both substantially influenced the objective or biologic response to toceranib, as their was similar among dogs experiencing CR/PR (60%) CB (52%) and dogs experiencing PD (45%).

There are several limitations inherent in the approach used to gather information in this retrospective study including no standard procedures for confirming a histopathologic or cytologic diagnosis, for staging/restaging, for recheck exams/bloodwork schedule, and for documentation of responses. Additionally, there were multiple clinicians involved at multiple sites and therefore no standard procedures for assessment of clinical toxicities and dose modifications. Lastly, there was no limit to the number and type of concomitant medications used or the type/duration of metronomic therapy used. As such, the data generated from this analysis would be classified as no higher than Type IV clinical evidence based on the concept of evidence-based medicine²⁸. Therefore, this study is most valuable in generating rather than testing clinical hypotheses, serving as a platform for the design of future prospective clinical trials to evaluate the true biologic activity of toceranib in canine solid tumors.

Conclusions

The data reported in this retrospective analysis suggests that toceranib may have biologic activity in a variety of solid tumors in dogs. Additionally, these data indicate that the administration of toceranib at doses lower than the MTD may still be associated with CB and may therefore be conducive to long-term drug administration. Future prospective studies are necessary to determine the true utility of toceranib in the treatment of canine solid tumors as well as to identify the role of additional metronomic therapeutics in toceranib based protocols.

Acknowledgments

Toceranib was provided by Pfizer Animal Health at no cost for the treatment of dogs included in this retrospective analysis.

References

1. London CA, Hannah AL, Zadovskaya R, Chien MB, Kollias-Baker C, Rosenberg M, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. *Clin Cancer Res.* 2003; 9(7):2755–68. [PubMed: 12855656]
2. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. *Clin Cancer Res.* 2009; 15(11):3856–65. [PubMed: 19470739]
3. Pryer NK, Lee LB, Zadovskaya R, Yu X, Sukbuntherng J, Cherrington JM, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. *Clin Cancer Res.* 2003; 9(15):5729–34. [PubMed: 14654558]
4. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. *J Clin Oncol.* 2007; 25(7):884–96. [PubMed: 17327610]
5. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. *Anticancer Drugs.* 2010; 21(1):S3–11. [PubMed: 20110785]
6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res.* 2003; 9(1):327–37. [PubMed: 12538485]
7. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. *Mol Cancer Ther.* 2006; 5(5):1280–9. [PubMed: 16731761]
8. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. *Expert Opin Investig Drugs.* 2009; 18(6):821–34.
9. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. *BioDrugs.* 2009; 23(6):377–89. [PubMed: 19894779]
10. Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. *J Steroid Biochem Mol Biol.* 2008; 108(3-5):261–6. [PubMed: 17945482]
11. Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. *Neuroendocrinology.* 2009; 90(4):323–48. [PubMed: 19468197]
12. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. *Mol Aspects Med.* 2010; 31(2):215–26. [PubMed: 20176050]
13. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. *Oncologist.* 2010; 15(2):146–56. [PubMed: 20142332]

14. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. *J Clin Oncol.* 2008; 26(29):4714–9. [PubMed: 18541894]
15. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. *J Clin Oncol.* 2009; 27(10):1675–84. [PubMed: 19255327]
16. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *J Clin Oncol.* 2010; 28(14):2323–30. [PubMed: 20368568]
17. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. *Anticancer Drugs.* 2008; 19(5):547–52. [PubMed: 18418222]
18. Christopoulos A, Ahn SM, Klein JD, Kim S. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: Beyond angiogenesis. *Head Neck.* 2010
19. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. *Head Neck.* 2003; 25(6):464–74. [PubMed: 12784238]
20. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. *Laryngoscope.* 2001; 111(10):1834–41. [PubMed: 11801954]
21. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. *J Clin Oncol.* 2007; 25(24):3766–73. [PubMed: 17704426]
22. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. *Cancer Chemother Pharmacol.* 2010; 65(4):649–60. [PubMed: 19655144]
23. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. *Nat Rev Clin Oncol.* 2010; 7(8):455–65. [PubMed: 20531380]
24. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. *J Clin Oncol.* 2008; 26(30):4899–905. [PubMed: 18794539]
25. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. *J Chemother.* 2008; 20(5):632–9. [PubMed: 19028628]
26. Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M, Bjarnason GA. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. *Cancer Chemother Pharmacol.* 2007; 60(1):135–41. [PubMed: 17009033]
27. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. *J Pediatr Hematol Oncol.* 2006; 28(11):720–8. [PubMed: 17114958]
28. Sahara A, Khanna C. A survey of evidence in the Journal of Veterinary Internal Medicine oncology manuscripts from 1999 to 2007. *J Vet Intern Med.* 2010; 24(1):51–6. [PubMed: 19780934]

1a

Pre

Post

1b

Pre

Post

Figure 1. Response of AGASACA to toceranib

- a). An 8 year old MC mix breed with metastatic AGASACA to the sublumbar lymph nodes and lungs was treated with toceranib after recurrence post surgery, radiation therapy and chemotherapy. Pictured above are radiographs prior to the start of Palladia and again at day 46 of therapy. Regression of several pulmonary metastatic lesions are noted.
- b). A 9 year old spayed female Golden retriever with metastatic AGASACA to the iliac lymph nodes, retroperitoneal space, and lungs was treated with toceranib after having failed surgery and multiple rounds of chemotherapy. Shown is a radiograph of her caudal abdomen prior to toceranib administration, and then again 4 weeks later demonstrating regression of her iliac lymph nodes. She also experienced regression of her pulmonary nodules (not shown).

Figure 2. Stable metastatic OSA following toceranib administration

A 9 year old spayed female mixed breed dog was placed on toceranib therapy after developing pulmonary metastasis 8 months following amputation and chemotherapy for OSA. Shown are thoracic radiographs prior to and 5 months after beginning toceranib; the metastatic lesion is circled. This dog did eventually go on to develop additional pulmonary lesions consistent with metastatic osteosarcoma.

3a

Pre

Post

3b

Figure 3. Response of metastatic thyroid carcinoma to toceranib

a. A 15 year old intact male Shih Tzu presented with a primary thyroid carcinoma and pulmonary metastasis. Toceranib therapy was initiated resulting in partial regression of the primary tumor (not shown) and complete regression of the pulmonary metastases. Shown are thoracic radiographs prior to and 4 weeks after beginning toceranib.

b. A 9 year old male neutered Labrador retriever presented with metastatic thyroid carcinoma in May 2009. He underwent surgical excision of the primary mass and 5 cycles of chemotherapy with a doxorubicin/cyclophosphamide/5-fluoruracil regimen. He experienced progression of his pulmonary metastases and was placed on toceranib. Shown are his thoracic radiographs prior to initiating toceranib in September 2009 and 5 months later in February 2010.

Pre

Post

Figure 4. Regression of oral squamous cell carcinoma after toceranib therapy

A 13 year old spayed female Labrador retriever mix presented with a large oral squamous cell carcinoma involving the caudal left maxilla. The owner elected to pursue toceranib therapy alone. Shown are pictures of the mass prior to treatment and again after near complete response to therapy.

Figure 5. Serial CT demonstrating response of nasal carcinoma to toceranib

An 11 year old male neutered Shetland sheepdog was treated with toceranib following recurrence of a nasal carcinoma after initially responding to radiation therapy in January 2010. Shown are serial matched images of the nasal cavity 3 (July 2010) and 5 (September 2010) months after beginning toceranib therapy in April 2010.

Table 1

Summary of patient demographics, treatment, and outcome

	All	CR/PR	SD	CR/PR/SD	PD
Number of Dogs	85	20 (24%)	43 (51%)	63 (74%)	22 (26%)
Age	10 (3-18)	10 (7.5-13)	10 (3-18)	10 (3-18)	10 (4-13)
Gender					
FS	41	8	25	33	8
M	4	3	0	3	1
MC	40	9	18	27	13
Dose (mg/kg)	2.8 (2.2-3.25)	2.8 (2.48-3.25)	2.8 (2.2-3.25)	2.8 (2.2-3.25)	2.8 (2.2-3.25)
3 mg/kg	25 (29%)	6 (30%)	11 (26%)	17 (27%)	8 (36%)
<3 mg/kg	60 (71%)	14 (70%)	32 (74%)	46 (73%)	14 (64%)
MWF Schedule	50 (59%)	7 (35%)	30 (70%)	37 (59%)	13 (59%)
Metronomic Con Meds					
NSAID	17	6	5	11	6
Low-dose CTX	14	3	9	12	2
NSAID/CTX	12	3	7	10	2
Total	43 (51%)	12 (60%)	21 (49%)	33 (52%)	10 (45%)
Duration of Tx (wks)	N/A	22 (4-48+)	25 (10-50+)	23 (4-50+)	N/A